PolyPid to Host Key Opinion Leader Call Discussing D-PLEX₁₀₀ and the Prevention of Surgical Site Infections

PETAH TIKVA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will host a